BYSI
NASDAQBeyondSpring Inc.
News · 26 weeks23-20%
2025-12-142026-06-07
Mix2190d
- Insider8(38%)
- SEC Filings5(24%)
- Other5(24%)
- Earnings2(10%)
- Leadership1(5%)
Latest news
25 items- SECBeyondSpring Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BeyondSpring Inc. (0001677940) (Filer)
- PRBeyondSpring Announces Leadership Transition to Deliver Focused Execution on Its Confirmatory DUBLIN-4 Program and Long-Term ValueDr. Lan Huang, PhD, remains Chairman of BeyondSpring, committing her time to SEED Therapeutics, where she serves as Co-Founder, Chairman, and Chief Executive Officer — a structure designed to give each company a fully dedicated executive leaderDr. Jiangwen (Jen) Majeti, PhD, MBA, current BeyondSpring Director, appointed Vice Chairman — deepening Board-level governance and providing strategic continuityMin Qiu appointed Chief Executive Officer with a clear mandate: execute DUBLIN-4, extend Plinabulin's scientific optionality, and build BeyondSpring's global partner and investor baseNa Li appointed Chief Financial Officer to strengthen BeyondSpring's financial position and support capital mark
- PRBeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival benefit: 12-month OS rate of 78.1% and 24-month OS rate of 58.0% in a patient population with limited treatment optionsGood tolerability and immune activation: Along with increased frequencies of activated CD4+/CD8+ T cells post-treatment, hematology test also showed safety benefit with significantly higher levels of WBCs, neutrophils and platelets. FLORHAM PARK, N.J., June 02, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company
- PRBeyondSpring Announces Poster Presentation at 2026 ASCO Annual MeetingFLORHAM PARK, N.J., May 18, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced an upcoming poster presentation of Study 303, an investigator-initiated study supported by Merck, known as MSD outside of the United States and Canada, and BeyondSpring, in patients with 2L/3L NSCLC who progressed on PD-1/PD-L1 inhibitors, at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 through June 2 in Chicago, IL. Presentation details are as follows: Title: A Phase 2 Study of Plinabulin (Plin)/Doceta
- INSIDERChief Executive Officer Huang Lan gifted 260,582 units of Ordinary Shares (SEC Form 4)4 - BeyondSpring Inc. (0001677940) (Issuer)
- SECSEC Form 10-Q filed by BeyondSpring Inc.10-Q - BeyondSpring Inc. (0001677940) (Filer)
- SECBeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BeyondSpring Inc. (0001677940) (Filer)
- PRBeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate UpdateAACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline
- PRBeyondSpring Reports Compelling New Data: Plinabulin Advances Both the Anticancer Efficacy and Safety of ADC DrugsNew Preclinical Results at AACR 2026 Show Plinabulin Dramatically Improves Complete Response Rates and Survival When Combined with Leading ADC Drugs — With or Without Immunotherapy Plinabulin's GEF-H1 Agonist Mechanism Drives Synergistic Antitumor Activity And CIN Mitigation Across TOP1-ADC ± PD-1/PD-L1 Inhibitor Regimens in Preclinical Models FLORHAM PARK, N.J., April 22, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) today reported new preclinical data at the 2026 Annual Meeting of the American Association for Cancer Research (AACR) demonstrating that Plinabulin has the potential to enhance both the efficacy and tolerability of ADC therapy — potentially boosting anticancer re
- INSIDERSEC Form 4 filed by Kirkby Matthew4 - BeyondSpring Inc. (0001677940) (Issuer)
- INSIDERSEC Form 4 filed by Fabbio Patrick4 - BeyondSpring Inc. (0001677940) (Issuer)
- INSIDERSEC Form 4 filed by Delaney Brendan4 - BeyondSpring Inc. (0001677940) (Issuer)
- INSIDERSEC Form 4 filed by Majeti Jiangwen4 - BeyondSpring Inc. (0001677940) (Issuer)
- INSIDERSEC Form 4 filed by Lu Yingjuan June4 - BeyondSpring Inc. (0001677940) (Issuer)
- INSIDERSEC Form 4 filed by Huang Lan4 - BeyondSpring Inc. (0001677940) (Issuer)
- INSIDERSEC Form 4 filed by Xu Sihai4 - BeyondSpring Inc. (0001677940) (Issuer)
- PRBeyondSpring Announces Plinabulin and ADC Combination Poster Presentation at AACR Annual Meeting 2026FLORHAM PARK, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that the Company will have a poster presentation at the 2026 Annual Meeting of the American Association for Cancer Research ("AACR"), taking place on April 17 through 22, 2026 in San Diego, California. Presentation Details: Title: Plinabulin Boosts Antitumor Efficacy of Topoisomerase Inhibitor-based Antibody-drug Conjugates Without or With Immune Checkpoint InhibitorPresenter / Authors: Yingjuan June Lu, Xiaoyan He, Weiwei Cheng, Zhengyan Zhang,
- SECSEC Form 10-K filed by BeyondSpring Inc.10-K - BeyondSpring Inc. (0001677940) (Filer)
- PRBeyondSpring Files 2025 Annual Report on Form 10-KFLORHAM PARK, N.J., March 25, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI) ("BeyondSpring" or the "Company"), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced that it has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025 with the U.S. Securities and Exchange Commission ("SEC") on March 25, 2026. The annual report on Form 10-K, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Company's website at www.beyondspringpharma.com under "Latest Results" in the Investors section.The Company will pr
- SECBeyondSpring Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BeyondSpring Inc. (0001677940) (Filer)
- PRBeyondSpring Reports 2025 Year-End Financial ResultsPlinabulin (BeyondSpring's Lead Program): Phase 3 Survival Benefit Confirmed: Plinabulin combined with docetaxel demonstrated statistically significant overall survival benefit vs. standard of care docetaxel in EGFR wild-type NSCLC patients whose tumors progressed after first line therapy — DUBLIN-3 study results published in The Lancet Respiratory Medicine Confirmatory Trial Planned: Based on DUBLIN-3 Phase 3 data and US FDA discussions, BeyondSpring is advancing DUBLIN-4, a confirmatory global Phase 3 study in a biomarker-selected EGFR wild-type NSCLC patient population progressed on immune checkpoint inhibitors (NCT07361484)Overcoming Immunotherapy Resistance: Early clinical data at MD A
- PRBeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° ConferenceFLORHAM PARK, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced that the Company will participate in the Immuno-Oncology 360° (IO360°) Conference 2026, held February 10-12, 2026 in Boston, MA. Dr. Lan Huang, Co-Founder, Chairman, and CEO of BeyondSpring, will present on Plinabulin as a differentiated immuno-oncology asset designed to enhance PD-1/PD-LD blockade and highlight Plinabulin's unique mechanism of action and clinical development strategy. Presentation Details:Title: Overcoming PD-1/L1 Resistance: Translational Insights with PlinabulinTr
- SECSEC Form 8-K filed by BeyondSpring Inc.8-K - BeyondSpring Inc. (0001677940) (Filer)
- PRBeyondSpring Announces ESMO Asia Presentation on Plinabulin + Docetaxel Improving Survival in Large Phase 3 DUBLIN-3 Asian Subset for EGFR WT NSCLC Compared to Docetaxel, Strengthening the Case for a Global Registration PathConsistent OS benefit in an Asian subset with a strong HR of 0.69 for non-squamous patients, and meaningful safety advantage position Plinabulin as a late-stage candidate showing survival improvement in 2L/3L EGFR WT NSCLC. FLORHAM PARK, N.J., Dec. 12, 2025 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a clinical-stage biopharmaceutical company developing first-in-class immune-modulating cancer therapies, today announced results from the Asian subset (n=488) of its global Phase 3 DUBLIN-3 trial evaluating Plinabulin plus docetaxel compared to docetaxel alone in second- or third-line EGFR wild-type non-small cell lung cancer (NSCLC). Dublin-3's global intent-to-treat (ITT) patient d
- PRBeyondSpring Announces New Analyses of DUBLIN-3 Phase 3 Study Showing Survival Benefit of Plinabulin + Docetaxel in Post Anti-PD-(L)1 for Non-squamous EGFR WT NSCLC and a Reduction in Brain Metastasis Compared to Docetaxel at NACLC 2025In DUBLIN-3 non-squamous EGFR WT NSCLC patients who progressed after anti-PD-(L)1, Plinabulin + docetaxel showed consistent and clinically meaningful improvements in OS, PFS, and ORR, reinforcing Plinabulin as a late-stage therapy with consistent survival benefit in anti-PD-(L)1-progressed NSCLC patients. Supported by anti-cancer efficacy and safety in significant reduction exposure-adjusted grade 3/4 adverse events in DUBLIN-3, BeyondSpring will conduct DUBLIN-4, a global, double-blind Phase 3 registrational trial. This study will evaluate Plinabulin + docetaxel vs. docetaxel in non-squamous EGFR wild-type NSCLC after progression on anti-PD-(L)1 and chemotherapy, and is intended to serve as
BYSI FAQ
7 questionsWhat does BeyondSpring Inc. do?
BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents...Where does BYSI stock trade?
BeyondSpring Inc. (BYSI) is listed on NASDAQ.What sector and industry is BYSI in?
BeyondSpring Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did BeyondSpring Inc. go public?
BeyondSpring Inc. (BYSI) completed its IPO in 2017.What are analysts saying about BYSI?
BeyondSpring Inc. has had 8 recent analyst actions on file. The most recent action was from Jefferies: Hold with a $500.00 price target on 2021-12-02. Recent price targets cluster around $500.00.What companies are similar to BYSI?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare BYSI side-by-side with any of them on Quantisnow.How can I track BYSI on Quantisnow?
Quantisnow aggregates BeyondSpring Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BYSI to receive live email and push alerts on every new disclosure.